MedTrace Logo

Olanzapine in the Treatment of Anorexia Nervosa

NCT00592930 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-01-14

No results posted yet for this study

Summary

This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.

Conditions

  • Anorexia Nervosa

Interventions

DRUG

olanzapine

flexibly dosed oral olanzapine 2.5 to 15 mg/day

DRUG

placebo

Sponsors & Collaborators

Principal Investigators

  • Vivian Kafantaris, M.D. · Schneider Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
23 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2004-12-31
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00592930 on ClinicalTrials.gov